# Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy

> **NCT05132738** · NA · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Ripretinib treatment

## Key facts

- **NCT ID:** NCT05132738
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132738, "Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT05132738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*